N-({[1-(3,4-dichloro-benzyl)-azetidin-3-ylmethyl]-carbamoyl}-methyl)-2-methoxy-benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-({[1-(3,4-dichloro-benzyl)-azetidin-3-ylmethyl]-carbamoyl}-methyl)-2-methoxy-benzamide
• 英文别名: N-[2-[[1-[(3,4-dichlorophenyl)methyl]azetidin-3-yl]methylamino]-2-oxoethyl]-2-methoxybenzamide
• 化学式: C₂₁H₂₃Cl₂N₃O₃
• 分子量: 436.338
• InChiKey: KMVVMFLQZQDZBG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  70.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-amino-N-[1-(3,4-dichloro-benzyl)-azetidin-3-ylmethyl]-acetamide 、 邻甲氧基苯甲酸 在 [dimethylamino-([1,2,3]triazolo[4,5-b]pyridin-1-yloxy)-methylene]-dimethyl-ammonium hexafluorophosphate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 生成 N-({[1-(3,4-dichloro-benzyl)-azetidin-3-ylmethyl]-carbamoyl}-methyl)-2-methoxy-benzamide
  参考文献：
  名称：

  [EN] AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS
  [FR] COMPOSES ORGANIQUES

  摘要：

  公开号：

  WO2006015854A3

文献信息

• Azetidine Derivatives as Ccr-e Receptor
  申请人：Legrand Mark Darren

  公开号：US20070259848A1

  公开（公告）日：2007-11-08

  Compounds of formula I in free or salt form, wherein Ar, X, Y and T have the meanings as indicated in the specification, are useful for treating a condition mediated by CCR-3, particularly an inflammatory or allergic condition such as an inflammatory or obstructive airways disease. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  公式I的化合物，无论是自由形式还是盐形式，其中Ar、X、Y和T的含义如规范所示，可用于治疗由CCR-3介导的疾病，特别是炎症或过敏性疾病，如炎症性或阻塞性呼吸道疾病。还描述了含有这些化合物的制药组合物和制备这些化合物的方法。
• Azetidine derivatives as CCR-3 receptor antagonist
  申请人：Novartis AG

  公开号：US07691841B2

  公开（公告）日：2010-04-06

  Compounds of formula I in free or salt form, wherein Ar, X, Y and T have the meanings as indicated in the specification, are useful for treating a condition mediated by CCR-3, particularly an inflammatory or allergic condition such as an inflammatory or obstructive airways disease. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  化学式为I的化合物，无论是自由形式还是盐形式，其中Ar、X、Y和T的含义如规范中所示，可用于治疗由CCR-3介导的疾病，特别是炎症或过敏性疾病，如炎症性或阻塞性气道疾病。还描述了包含这些化合物的制药组合物和制备这些化合物的方法。
• Electrochemical deblocking solution for electrochemical oligomer synthesis on an electrode array
  申请人：CustomArray, Inc.

  公开号：US10006131B1

  公开（公告）日：2018-06-26

  There is disclosed an electrochemical deblocking solution for use on an electrode microarray. There is further disclosed a method for electrochemical synthesis on an electrode array using the electrochemical deblocking solution. The solution and method are for removing acid-labile protecting groups for synthesis of oligonucleotides, peptides, small molecules, or polymers on a microarray of electrodes while substantially improving isolation of deblocking to active electrodes. The method comprises applying a voltage or a current to at least one electrode of an array of electrodes. The array of electrodes is covered by the electrochemical deblocking solution.

  本发明公开了一种用于电极微阵列的电化学解锁溶液。还进一步公开了一种使用该电化学解锁溶液在电极阵列上进行电化学合成的方法。该溶液和方法用于去除酸性保护基团，以便在电极微阵列上合成寡核苷酸、肽、小分子或聚合物，同时大幅提高与活性电极的解锁隔离度。该方法包括向电极阵列中的至少一个电极施加电压或电流。电极阵列被电化学解锁溶液覆盖。
• High efficiency, small volume nucleic acid synthesis
  申请人：LIFE TECHNOLOGIES CORPORATION

  公开号：US10407676B2

  公开（公告）日：2019-09-10

  The disclosure generally relates to compositions and methods for the production of nucleic acid molecules. In some aspects, the invention allows for the microscale generation of nucleic acid molecules, optionally followed by assembly of these nucleic acid molecules into larger molecules. In some aspects, the invention allows for efficient production of nucleic acid molecules (e.g., large nucleic acid molecules such as genomes).

  本发明一般涉及生产核酸分子的组合物和方法。在某些方面，本发明可以微量生成核酸分子，然后将这些核酸分子组装成更大的分子。在某些方面，本发明可高效生产核酸分子（如基因组等大核酸分子）。
• AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS
  申请人：NOVARTIS AG

  公开号：EP1781606B1

  公开（公告）日：2009-08-05